Search Within

Howard Scher

Formats
  1. Journal Article (626)
  2. Meeting Abstract (463)
  3. Book Section (13)
  4. Conference Paper (11)
  5. Editorial (7)
  6. Review (6)
  7. Guidelines (3)
  8. Correspondence (2)
  9. Research Letter (2)
Groups
  1. Department of Medicine (1133)
  2. Genitourinary Oncology Service (1133)
  3. Solid Tumor Oncology Division (1133)
  4. GSK Faculty (305)
  5. Sloan Kettering Institute Faculty (249)
  6. Department of Pathology and Laboratory Medicine (241)

More Groups

People
  1. Michael Morris (217)
  2. Susan Slovin (140)
  3. Dana Rathkopf (133)
  4. Daniel Danila (112)
  5. Steven Larson (110)
  6. Victor Reuter (97)

More People

Years
  1. 2025 (11)
  2. 2024 (12)
  3. 2023 (15)
  4. 2022 (25)
  5. 2021 (19)
  6. 2020 (35)

More Years

Publications
  1. Journal of Clinical Oncology (328)
  2. Clinical Cancer Research (85)
  3. Cancer Research (54)
  4. Proceedings of the American Association for Cancer Research Annual Meeting (47)
  5. Journal of Urology (36)
  6. European Urology (35)

More Publications

Publishers
  1. American Society of Clinical Oncology (335)
  2. American Association for Cancer Research (197)
  3. Elsevier Science, Inc. (119)
  4. Elsevier Inc. (72)
  5. Nature Publishing Group (58)
  6. Oxford University Press (47)

More Publishers

Results (1133)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Predictive biomarkers in circulating tumor cells (CTC) from patients with castration-resistant prostate cancer (CRPC) through genomic analysis
    Meeting Abstract

    Danila, D. C.; Anand, A.; Yao, J.; Gierszewska, M.; Kramer, M.; Muller, S.; Fleisher, M.; McCombie, W. R.; Scher, H. I.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • 18F-16 beta-fluoro-5 alpha-dihydrotestosterone (FDHT) PET as a prognostic biomarker for survival in patients with metastatic castrate-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Autio, K. A.; Fox, J. J.; Jia, X.; Heller, G.; Schoder, H.; Humm, J.; Haupt, E. C.; Schneider, C.; Scher, H. I.; Larson, S. M.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: Results from the phase III AFFIRM study
    Meeting Abstract

    Scher, H. I.; Fizazi, K.; Saad, F.; Taplin, M. E.; Sternberg, C. N.; Miller, K.; De Wit, R.; Mulders, P.; Hirmand, M.; Selby, B.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Ipilimumab (IPI) in metastatic castrate-resistant prostate cancer (mCRPC): Results from an open-label, multicenter phase I/II study
    Meeting Abstract

    Slovin, S. F.; Hamid, O.; Tejwani, S.; Higano, C. S.; Harzstark, A.; Alumkal, J. J.; Scher, H. I.; Chin, K. M.; Gagnier, P.; McHenry, M. B.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Predictive biomarkers in circulating tumor cells (CTC) from patients with castration-resistant prostate cancer (CRPC) through genomic analysis
    Meeting Abstract

    Danila, D. C.; Anand, A.; Yao, J.; Gierszewska, M.; Kramer, M.; Muller, S.; Fleisher, M.; McCombie, W. R.; Scher, H. I.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Phase I/II safety and pharmacokinetic (PK) study of ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC): Phase I results of a Prostate Cancer Clinical Trials Consortium study
    Meeting Abstract

    Rathkopf, D. E.; Danila, D. C.; Morris, M. J.; Slovin, S. F.; Steinbrecher, J. E.; Arauz, G.; Rix, P. J.; Maneval, E. C.; Chen, I.; Fox, J. J.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Exploratory analysis of survival benefit and prior docetaxel (D) treatment in COU-AA-301, a phase III study of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Chi, K. N.; Scher, H. I.; Molina, A.; Logothetis, C.; Jones, R. J.; Staffurth, J.; North, S. A.; Vogelzang, N. J.; Saad, F.; Mainwaring, P. N.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Comparison of PSA, FDG-PET, and Prostate Cancer Working Group 2 (PCWG2) criteria to interpret apparent progression on first post-treatment bone scan
    Meeting Abstract

    Autio, K. A.; Fox, J. J.; Haupt, E. C.; Schoder, H.; Scher, H. I.; Larson, S. M.; Morris, M. J.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Pain control and delay in time to skeletal-related events (SREs) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA): Long-term follow-up
    Meeting Abstract

    Basch, E. M.; De Bono, J. S.; Scher, H. I.; Molina, A.; Sternberg, C. N.; Fizazi, K.; North, S. A.; Chi, K. N.; Jones, R. J.; Goodman, O. B.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Association of reduction in serum androgens and change in serum PSA in patients treated with abiraterone acetate (AA): A subset analysis of the COU-AA-301 phase 3 randomized trial
    Meeting Abstract

    Ryan, C.; Peng, W. P.; Kheoh, T.; Scher, H. I.; Molina, A.
    Cancer Research (2012)

    Fulltext@MSK | Save